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According to the World Health Organization (WHO), access to essential medications is one of the five indicators of progress in securing the right to health \[[@CR1]\]. Although the percentage of the global population without access to essential medications has decreased, approximately 1.3--2.1 billion people still lack access to essential medications \[[@CR2], [@CR3]\]. In developing countries, especially in Latin America, larger differences in medication consumption levels exist between population strata \[[@CR4]\]. Higher economic classes show consumption patterns similar to wealthier countries, while lower economic classes have difficulty in accessing basic medications \[[@CR5]\].

According to Cameron et al. \[[@CR6]\], even when medications are provided for free distribution or at low cost to the public sector, access is limited as a result of low availability. This low availability may result from a combination of factors such as inadequate funding, lack of incentives for stock maintenance, the inability to predict demand accurately, inefficient distribution systems or diversion of medications to the private sector.

Although the Brazilian Public Health System \[Sistema Único de Saúde (SUS)\] has the duty to provide medications for the treatment of diabetes that are included in the national list of essential medicines \[[@CR7], [@CR8]\], Bahia et al. \[[@CR9]\] found that 24.6 % of patients with diabetes in Brazil bought their medications from private pharmacies.

To increase access to medications in Brazil, in 2006 the state began to subsidize approximately 90 % of the cost of drugs used for the treatment of diabetes and hypertension through a co-payment system associated with the Ministry of Health that covered medications purchased from private pharmacies \[[@CR10]\]. In February 2011, this policy was expanded with the creation of the "Health Has No Price" Program \[Programa Saúde Não Tem Preço (SNTP)\], in which associated pharmacies began to provide two types of insulin (regular human insulin and isophane insulin or NPH) and three oral antidiabetic medications (glibenclamide 5 mg, metformin 500 and 850 mg) free of charge, with a subsequent reimbursement of the amount agreed upon between the government and the pharmaceutical industry \[[@CR11]\]. In this context, the objective of our study was to evaluate the impact of the SNTP Program on the access to medications for diabetes treatment in Brazil.

Methods {#Sec2}
=======

We performed a longitudinal observational study of the access to antidiabetic medications in Brazil after the implementation of the SNTP Program. Data were collected from 55,000 pharmacies, representing approximately 76 % of private pharmacy establishments in the country, from February 1, 2010 to January 31, 2012 \[[@CR12]\]. The number of tablets (oral antidiabetic medication) and the international units (insulin and insulin analogues) supplied free of charge during the first 12 months of the SNTP Program were compared with those supplied under the co-payment system in the 12 months prior to the implementation of the program. The oral antidiabetic tablets selected were from two subgroups of the anatomical therapeutic chemical (ATC) WHO classification, which consisted of medicines in the SNTP Program (biguanides and sulfonylureas). In addition, an insulin subgroup was also included in the study. A similar analysis was performed with three fixed-dose combinations not included in the SNTP Program (two containing oral antidiabetics and one combined with insulin).

Results {#Sec3}
=======

The number of supplied units of all medicines for the treatment of diabetes in the SNTP Program increased in the first 12 months of the SNTP Program compared with the 12 months prior to the implementation of the program. The percentage of variation ranged from 39.9 to 97.8 %. Four sulfonylureas (glibenclamide, glimepiride, glipizide and chlorpropamide), one biguanide (metformin) and three fixed-dose combinations marketed in Brazil were included in the analysis of oral antidiabetic medications. The number of tablets supplied in the SNTP program increased from 39.9 to 65.9 % in the first year of the program. No other oral antidiabetic medication showed a comparable increase in the number of units supplied. The number of tablets dispensed (none in the SNTP Program) of the three fixed-dose combinations analyzed decreased after implementation of the SNTP Program (Table [1](#Tab1){ref-type="table"}).Table 1Number of oral antidiabetics tablets supplied in the first 12 months of the SNTP Program (free of charge) and in the 12 months before to the Program (copayment system)MedicinesATCFeb. 2010--Jan. 2011Feb. 2011--Jan. 2012Percentage of chargeMedicines included in SNTP Program Glibenclamide 5 mgA10BB01158,388,380262,747,85065.9 Metformin 500 mgA10BA02289,027,638424,146,87846.8 Metformin 850 mgA10BA02283,321,454396,338,21639.9Medicines not included in SNTP Program Single-drug formulations  Glimepiride 4 mgA10BB1238,372,01045,749,97019.2  Metformin 1000 mgA10BA0212,940,38014,202,1109.8  Glimepiride 2 mgA10BB1263,221,31067,166,1906.2  Glipizide 5 mgA10BB071,415,3401,300,020−8.2  Chlorpropamide 250 mgA10BB0217,151,54014,763,550−13.9Fixed-dose combinations Glibenclamide + metformin (1 mg + 500 mg)^a^A10BD0225,764,51022,236,330−13.7 Glibenclamide + metformin (5 mg + 500 mg)^b^A10BD0241,330,99036,197,800−12.4 Glibenclamide + metformin (2,5 mg + 500 mg)^a^A10BD0212,895,20011,573,430−10.3Brazil, February 2010 through January 2012Adapted from information published \[[@CR12]\]*ATC* Anatomical therapeutic chemical^a^ Only one of the combination of drugs is contemplated in the SNTP Program at the same concentration^b^ Both drugs are included in the combination SNTP Program at the same concentrations

A similar evaluation was performed with insulin and the insulin analogues marketed in Brazil. The two types of insulins included in the SNTP Program showed the highest percentage of change in the number of international units dispensed, even when compared with the oral antidiabetics. The only form of insulin that showed a decrease in the number of international units supplied after the implementation of the program was the fixed-dose combination of regular human insulin and isophane insulin. Also, the insulin analogues not included in the SNTP Program (insulin lispro, glulisine, glargine, aspart and detemir) showed an increase in the number of international units dispensed (Table [2](#Tab2){ref-type="table"}).Table 2Number of international units supplied in the first 12 months of the SNTP Program (free of charge) and in the 12 months before to the Program (copayment system)MedicinesATCFeb. 2010--Jan. 2011Feb. 2011--Jan. 2012Percentage of chargeMedicines included in SNTP Program Regular human insulinA10AB011,122,9872,221,32497.8 Isophane insulin (NPH)A10AC0111,435,13120,352,05478.0Medicines not included in SNTP Program Single-drug formulations  Insulin glulisineA10AB06429,221575,88334.2  Insulin detemirA10AE051,644,9451,864,98013.4  Insulin lisproA10AC041,278,9321,396,6439.2  Insulin aspartA10AB051,554,7051,696,2809.1  Insulin glargineA10AE043,328,1093,533,3369.1Fixed-dose combinations Regular human insulin + isophane insulin (NPH)^a^A10AD30626,589595,233−5.0Brazil, February 2010 through January 2012Adapted from information published \[[@CR12]\]*ATC* Anatomical therapeutic chemical^a^ Both drugs are included in the combination SNTP Program at the same concentrations
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This is the first study describing the impact of the SNTP Program on the access to antidiabetics in Brazil. The results confirmed a significant expansion of access to the diabetes treatment medications included in the SNTP Program, especially compared with other medications of the same therapeutic classes that are available in the Brazilian market. The analysis of the percentage change in the number of oral antidiabetic tablets and the number of international units of insulin supplied, whether as single agents or fixed-dose combinations, indicates that access expansion was greater for medicines included in the SNTP Program.

It was further observed that a lack of some fixed-dose combinations in the SNTP Program may result in the prescription of two individual medicines. The four fixed-dose combinations analyzed and formulated with active ingredients of single agents can be obtained at no cost in associated pharmacies. These combinations exhibited a decrease in the number of units dispensed after the start of the SNTP Program. This result may indicate a preference for the prescription of medicines available through the program.

The implementation of the SNTP Program, through an agreement between private pharmacies and the Ministry of Health, increased the access to medicines for the treatment of diabetes in Brazil. Also, the number of associated pharmacies increased from 14,003 in December 2010 to 22,470 establishments in July 2013, covering 3664 cities \[[@CR13], [@CR14]\].

The initiative by the Ministry of Health to subsidize the purchase of medications in private pharmacies began in 2006 through a co-payment system in which the government was responsible for approximately 90 % of the cost of some antidiabetic and antihypertensive medicines. From 2011, the government began to pay the full cost of medications included in the SNTP program \[[@CR9], [@CR10]\]. The considerable increase in the number of antihypertensive medicines supplied during the implementation of the SNTP Program \[[@CR14]\] confirms, once again, that the price of the medicine is an essential determinant of the economic accessibility and financial sustainability for individuals \[[@CR15]\].

Mortality due to diabetes declined in Brazil over the 15 years between 1996 and 2011, minimally in men but considerably in women \[[@CR16]\]. However, recent studies have shown a high prevalence of diabetes in Brazilian adults over time (11.9 %), with a progressive increase in the last 35 years \[[@CR17]\]. It is estimated that hospitalization due to diabetes is responsible for 2.2 % of the Ministry of Health budget \[[@CR18]\], and that 80 % of patients diagnosed with diabetes in the country (approximately 7.5 million) are assisted by SUS. Further, 57.4 % of patients with diabetes aged over 18 years received at least one medication for diabetes treatment in the Brazilian SNTP program in 2013 \[[@CR18]--[@CR20]\].

The number of dispensed units of oral antidiabetic medications included in the SNTP Program was eight times higher than the growth in the pharmaceutical market in Brazil during the same period (12.7 %). The highest percentage increase in oral antidiabetics was observed for 5 mg glibenclamide (65.9 %). The highest variation in the number of tablets was for 500 mg metformin, with an increase of over 135 million tablets compared with the 12 months preceding the implementation of the SNTP Program.

The insulin medications included in the SNTP Program showed the greatest significant changes in the number of international units dispensed. The increase was 97.8 % for regular human insulin and 78.0 % for isophane insulin (NPH). Among the antidiabetic medications not included in the SNTP program, only insulin glulisine significantly increased (34.2 %), but this increase was still less than the growth observed for the insulin types included in the program.

Despite the observed increase in the number of international units of insulin analogues dispensed, health technology assessments conducted by the National Technology Implementation Commission (Comissão Nacional de Incorporação de Tecnologias-Conitec) for SUS in 2013, recommended against the inclusion of the fast-acting insulin analogues (lispro, aspart and glulisine) for the treatment of type 1 diabetes \[[@CR21]\] and the long-acting insulin analogues (detemir and glargine) for the treatment of types 1 and 2 diabetes patients \[[@CR22]\].

It is important to note that a limitation of the results of this study did not include medicines used in hospital or dispensed for free at pharmacies of the Brazilian Public Health System, which according to Gialdi \[[@CR23]\], represent approximately 30 % of medication consumption in Brazil. This study also did not address the economic aspects such as the amount reimbursed by the State to private pharmacies, which has been criticized for being much higher than the amount paid for the purchase of the same medications for distribution in the Brazilian Public Health System.

Conclusions {#Sec5}
===========

The results of this study reveal that the SNTP Program has significantly contributed to an increase in access to medications for the treatment of diabetes, indicating that this public health policy has achieved its goal.
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